SAN DIEGO, Aug. 2 /PRNewswire/ -- Novalar Pharmaceuticals, Inc., a specialty pharmaceutical company focused in dental, today announced that OraVerse®, the company's premier pharmaceutical product, has ...

Septodont has acquired the OraVerse product line from Novalar Pharmaceuticals, the companies announced today. OraVerse is the first local anesthesia reversal agent to gain U.S. Food and Drug ...

Novalar has received approval to market OraVerse (phentolamine mesylate injection) for the reversal of soft-tissue anesthesia and the associated functional deficits resulting from a local dental ...

The U.S. FDA has asked Novalar Pharmaceuticals to stop distributing a patient brochure for the drug OraVerse (phentolamine mesylate), which it markets for reversing the effects of local anesthesia.

SAN DIEGO, May 12 /PRNewswire/ -- Novalar Pharmaceuticals, Inc., a dental specialty pharmaceutical company, announced today that the United States Food and Drug Administration (FDA) has granted ...

The FDA has approved OraVerse, the first drug indicated for reversing the effects of local anesthesia used by dentists. According to Novalar Pharmaceuticals, the drug company that makes OraVerse, the ...

SAN DIEGO, May 12 Novalar Pharmaceuticals, Inc., a dentalspecialty pharmaceutical company, announced today that the United States Foodand Drug Administration (FDA) has granted marketing approval for ...

SAN FRANCISCO (CBS 5) - Bay Area dental patients that don't like dealing with a day of face numbness may be in luck - thanks to a drug that promises to counteract the local anesthetic that dentists ...